Short-Term Exposure to Ambient Air Pollution and Antimicrobial Use for Acute Respiratory Symptoms.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
03 Sep 2024
Historique:
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 6 9 2024
Statut: epublish

Résumé

Ambient air pollution and antimicrobial resistance pose significant global public health challenges. It is not known whether ambient air pollution is associated with increased consumption of antimicrobials. To assess whether a short-term association exists between ambient air pollution levels and antimicrobial consumption among the general population seeking primary care consultations for acute respiratory symptoms. This 2-stage cross-sectional ecological time series analysis study using data on daily ambient air pollution and antimicrobial consumption was conducted in the 11 largest cities in Catalonia, Spain, from June 23, 2012, to December 31, 2019, among all inhabitants aged 12 years or older. Statistical analysis was performed from November 2022 to December 2023. Daily ambient air pollution (particulate matter of 10 μg/m3 [PM10], particulate matter of 2.5 μg/m3 [PM2.5], and nitrogen dioxide [NO2]). The main outcome was antimicrobial consumption associated with primary care consultations for acute respiratory symptoms in the 30 days before and after the dispensing of the antimicrobial. Antimicrobial consumption was measured as defined daily doses (DDDs) per 1000 inhabitants per day. Among 1 938 333 inhabitants (median age, 48 years [IQR, 34-65 years]; 55% female participants), there were 8 421 404 antimicrobial dispensations, with a median of 12.26 DDDs per 1000 inhabitants per day (IQR, 6.03-15.32 DDDs per 1000 inhabitants per day). The median adjusted morbidity score was 2.0 (IQR, 1.0-5.0). For the 1 924 814 antimicrobial dispensations associated with primary care consultations for acute respiratory symptoms, there was a significant correlation between increases of 10 μg/m3 in the concentration of the 3 pollutants studied and heightened antimicrobial consumption at day 0 (PM10: relative risk [RR], 1.01 [95% CI, 1.01-1.02]; PM2.5: RR, 1.03 [95% CI, 1.01-1.04]; NO2: RR, 1.04 [95% CI, 1.03-1.05]). A delayed association emerged between increases in PM2.5 concentration and antimicrobial consumption between day 7 (RR, 1.00 [95% CI, 1.00-1.01]) and day 10 (RR, 1.00 [95% CI, 1.00-1.01]) after exposure. In this 2-stage cross-sectional study using ecological time series analysis, short-term exposure to air pollution was associated with increased antimicrobial use associated with primary care consultations for acute respiratory symptoms in the general population. This finding could contribute to informing policy decisions aimed at reducing air pollution and its associated risks, thereby promoting respiratory health and reducing antimicrobial use.

Identifiants

pubmed: 39240563
pii: 2823297
doi: 10.1001/jamanetworkopen.2024.32245
doi:

Substances chimiques

Particulate Matter 0
Anti-Infective Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2432245

Auteurs

Gabriela Abelenda-Alonso (G)

Department of Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de LLobregat, Barcelona, Catalonia, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Consortium for Biomedical Research in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Pau Satorra (P)

Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Catalonia, Spain.

Marc Marí-Dell'Olmo (M)

Public Health Agency of Barcelona, Barcelona, Catalonia, Spain.
Sant Pau Biomedical Research Institute (IIB Sant Pau), Barcelona, Catalonia, Spain.
Consortium for Biomedical Research in the Epidemiology and Public Health Network (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.

Cristian Tebé (C)

Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Catalonia, Spain.

Ariadna Padullés (A)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Consortium for Biomedical Research in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Department of Pharmacy, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.

Andrea Vergara (A)

Department of Microbiology, Hospital Clínic, Barcelona, Catalonia, Spain.

Carlota Gudiol (C)

Department of Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de LLobregat, Barcelona, Catalonia, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Consortium for Biomedical Research in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalonia, Spain.

Miquel Pujol (M)

Department of Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de LLobregat, Barcelona, Catalonia, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Consortium for Biomedical Research in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Jordi Carratalà (J)

Department of Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de LLobregat, Barcelona, Catalonia, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Consortium for Biomedical Research in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalonia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH